MACKAY MARTIN 4

What Happened

• Martin Mackay, a director of Kailera Therapeutics (KLRA), received a derivative award on April 16, 2026 covering 38,300 shares. The award was reported on a Form 4 filed April 20, 2026. The reported acquisition price is $0.00, indicating an equity award (e.g., options or RSUs) rather than an open‑market purchase.

Key Details

• Transaction date: 2026-04-16; Form 4 filed: 2026-04-20 (filed within the standard reporting window).
• Transaction type/code: A — Grant/award (derivative securities).
• Shares/units granted: 38,300 (acquired at $0.00 per share as reported).
• Vesting: Footnote F1 states the award vests 100% on April 16, 2027, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No sign of an immediate exercise or sale; this is a compensation grant, not a market purchase or sale.

Context

• Awards to directors are commonly part of board compensation and do not necessarily signal the director buying or selling stock. Because this is a derivative award with a one‑year vesting condition, the economic interest is contingent on continued service and any future exercise/settlement terms (not detailed here).